424 related articles for article (PubMed ID: 23297343)
21. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
[TBL] [Abstract][Full Text] [Related]
22. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
[TBL] [Abstract][Full Text] [Related]
23. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
24. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
[TBL] [Abstract][Full Text] [Related]
25. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis.
Morrison MM; Young CD; Wang S; Sobolik T; Sanchez VM; Hicks DJ; Cook RS; Brantley-Sieders DM
PLoS Genet; 2015 Jul; 11(7):e1005291. PubMed ID: 26132202
[TBL] [Abstract][Full Text] [Related]
26. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
[TBL] [Abstract][Full Text] [Related]
27. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
28. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
29. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
30. AMPD1 regulates mTORC1-p70 S6 kinase axis in the control of insulin sensitivity in skeletal muscle.
Tandelilin AA; Hirase T; Hudoyo AW; Cheng J; Toyama K; Morisaki H; Morisaki T
BMC Endocr Disord; 2015 Mar; 15():11. PubMed ID: 25887856
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
32. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
Harada K; Miyake H; Kumano M; Fujisawa M
Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
[TBL] [Abstract][Full Text] [Related]
33. Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses.
Kaur S; Sassano A; Majchrzak-Kita B; Baker DP; Su B; Fish EN; Platanias LC
Proc Natl Acad Sci U S A; 2012 May; 109(20):7723-8. PubMed ID: 22550181
[TBL] [Abstract][Full Text] [Related]
34. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
35. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
36. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size.
Saci A; Cantley LC; Carpenter CL
Mol Cell; 2011 Apr; 42(1):50-61. PubMed ID: 21474067
[TBL] [Abstract][Full Text] [Related]
37. Mitotic raptor promotes mTORC1 activity, G(2)/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation.
Ramírez-Valle F; Badura ML; Braunstein S; Narasimhan M; Schneider RJ
Mol Cell Biol; 2010 Jul; 30(13):3151-64. PubMed ID: 20439490
[TBL] [Abstract][Full Text] [Related]
38. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
39. Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons.
Urbanska M; Gozdz A; Swiech LJ; Jaworski J
J Biol Chem; 2012 Aug; 287(36):30240-56. PubMed ID: 22810227
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
Sini P; James D; Chresta C; Guichard S
Autophagy; 2010 May; 6(4):553-4. PubMed ID: 20364113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
